Enlivex (ENLV) director Hart Gili reports option and share holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Enlivex Ltd. director Hart Gili filed an initial ownership report showing existing equity and option positions, with no new buy or sell transactions reported. The filing lists direct ownership of 7,672 ordinary shares and two option grants over 66,489 and 3,382 underlying ordinary shares. One option has a strike price of $2.69 and expires on December 31, 2033, and another has a strike price of $5.34 and expires on November 17, 2032. A footnote states that one option grant vests in equal annual installments over four years beginning on November 17, 2023.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Hart Gili
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares, par value NIS 0.40 per share | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 66,489 shares (Direct);
Ordinary Shares, par value NIS 0.40 per share — 7,672 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What does Enlivex (ENLV) director Hart Gili report in this Form 3?
Hart Gili reports existing holdings in Enlivex, including ordinary shares and stock options. The filing is an initial ownership statement, showing positions but no new purchases or sales, giving investors a snapshot of this director’s current equity exposure.
When do Hart Gili’s Enlivex (ENLV) stock options expire?
One option grant over Enlivex ordinary shares expires on December 31, 2033, and another expires on November 17, 2032. These expiration dates define how long the director can choose to exercise the respective options at their stated exercise prices.
How do Hart Gili’s Enlivex (ENLV) options vest over time?
A footnote states that one option grant vests in equal annual installments over four years beginning on November 17, 2023. This means portions of the option become exercisable each year, aligning the director’s incentives with longer-term company performance.